Dalteparin sodium injection + Warfarin

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Deep-Vein Thrombosis

Conditions

Deep-Vein Thrombosis

Trial Timeline

Sep 1, 2002 → Dec 1, 2011

NCT ID

NCT00245856

About Dalteparin sodium injection + Warfarin

Dalteparin sodium injection + Warfarin is a approved stage product being developed by Pfizer for Deep-Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00245856. Target conditions include Deep-Vein Thrombosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00245856	Approved	Completed	Sep 1, 2002	Dec 1, 2011	Deep-Vein Thrombosis

Competing Products

1 competing product in Deep-Vein Thrombosis

See all competitors

Product	Company	Stage	Hype Score
Apixaban	Bristol Myers Squibb	Phase 2	51

Other Products from Pfizer